Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the
treatment of social withdrawal in subjects with autism spectrum disorders